Tower Research Capital (TRC)’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.82K | Buy |
+511
| New | +$5.4K | ﹤0.01% | 4467 |
|
|
2026
Q1 | – | Sell |
-109
| Closed | -$1.39K | – | 5185 |
|
|
2025
Q4 | $1.39K | Sell |
109
-171
| -61% | -$2.63K | ﹤0.01% | 4702 |
|
|
2025
Q3 | $5.24K | Buy |
280
+203
| +264% | +$4K | ﹤0.01% | 4255 |
|
|
2025
Q2 | $1.97K | Sell |
77
-198
| -72% | -$3.98K | ﹤0.01% | 4716 |
|
|
2025
Q1 | $5.5K | Buy |
275
+170
| +162% | +$3.58K | ﹤0.01% | 4118 |
|
|
2024
Q4 | $1.91K | Sell |
105
-44
| -30% | -$864 | ﹤0.01% | 4941 |
|
|
2024
Q3 | $4.47K | Sell |
149
-936
| -86% | -$20.5K | ﹤0.01% | 4534 |
|
|
2024
Q2 | $15.3K | Buy |
1,085
+684
| +171% | +$11.9K | ﹤0.01% | 3916 |
|
|
2024
Q1 | $7.62K | Buy |
401
+93
| +30% | +$1.81K | ﹤0.01% | 4176 |
|
|
2023
Q4 | $6.83K | Buy |
308
+268
| +670% | +$7.96K | ﹤0.01% | 4693 |
|
|
2023
Q3 | $1.51K | Buy |
40
+33
| +471% | +$1.89K | ﹤0.01% | 5317 |
|
|
2023
Q2 | $524 | Buy |
+7
| New | +$443 | ﹤0.01% | 5606 |
|
|
2022
Q4 | – | Sell |
-48
| Closed | -$1K | – | 5949 |
|
|
2022
Q3 | $1K | Buy |
+48
| New | +$1.88K | ﹤0.01% | 5745 |
|
|
2022
Q2 | – | Sell |
-341
| Closed | -$22K | – | 6130 |
|
|
2022
Q1 | $22K | Sell |
341
-1,409
| -81% | -$101K | ﹤0.01% | 3427 |
|
|
2021
Q4 | $146K | Buy |
1,750
+328
| +23% | +$36.8K | ﹤0.01% | 1987 |
|
|
2021
Q3 | $231K | Sell |
1,422
-17
| -1% | -$2.76K | 0.01% | 1682 |
|
|
2021
Q2 | $218K | Buy |
1,439
+1,215
| +542% | +$205K | 0.01% | 1848 |
|
|
2021
Q1 | $39K | Sell |
224
-5
| -2% | -$953 | ﹤0.01% | 3329 |
|
|
2020
Q4 | $36K | Sell |
229
-1,632
| -88% | -$273K | ﹤0.01% | 3416 |
|
|
2020
Q3 | $297K | Buy |
1,861
+1,529
| +461% | +$276K | ﹤0.01% | 2198 |
|
|
2020
Q2 | $66K | Buy |
+332
| New | +$61K | ﹤0.01% | 2826 |
|
|
2020
Q1 | – | Sell |
-199
| Closed | -$15K | – | 3175 |
|
|
2019
Q4 | $15K | Buy |
199
+86
| +76% | +$7.5K | ﹤0.01% | 2095 |
|
|
2019
Q3 | $11K | Sell |
113
-34
| -23% | -$3.96K | ﹤0.01% | 2860 |
|
|
2019
Q2 | $20K | Sell |
147
-125
| -46% | -$17.2K | ﹤0.01% | 2172 |
|
|
2019
Q1 | $41K | Buy |
272
+242
| +807% | +$37.7K | ﹤0.01% | 1865 |
|
|
2018
Q4 | $5K | Buy |
+30
| New | +$5.96K | ﹤0.01% | 2887 |
|
|
2018
Q2 | – | Sell |
-54
| Closed | -$8K | – | 3703 |
|
|
2018
Q1 | $8K | Buy |
54
+15
| +38% | +$2.27K | ﹤0.01% | 2536 |
|
|
2017
Q4 | $5K | Buy |
+39
| New | +$4.96K | ﹤0.01% | 2872 |
|
|
2017
Q3 | – | Sell |
-3
| Closed | – | – | 3822 |
|
|
2017
Q2 | $0 | Sell |
3
-2
| -40% | -$175 | ﹤0.01% | 2818 |
|
|
2017
Q1 | $0 | Sell |
5
-67
| -93% | -$7.49K | ﹤0.01% | 3182 |
|
|
2016
Q4 | $8K | Buy |
72
+68
| +1,700% | +$7.44K | ﹤0.01% | 2765 |
|
|
2016
Q3 | $1K | Sell |
4
-31
| -89% | -$3.22K | ﹤0.01% | 3274 |
|
|
2016
Q2 | $3K | Sell |
35
-38
| -52% | -$3.31K | ﹤0.01% | 3671 |
|
|
2016
Q1 | $5K | Sell |
73
-76
| -51% | -$6.6K | ﹤0.01% | 2664 |
|
|
2015
Q4 | $17K | Buy |
149
+141
| +1,763% | +$19.2K | ﹤0.01% | 1458 |
|
|
2015
Q3 | $1K | Sell |
8
-2
| -20% | -$267 | ﹤0.01% | 3584 |
|
|
2015
Q2 | $1K | Sell |
10
-15
| -60% | -$2.04K | ﹤0.01% | 3972 |
|
|
2015
Q1 | $7K | Buy |
+25
| New | +$5.14K | ﹤0.01% | 3032 |
|
Other funds holding CTSO
CM
Tower Research Capital (TRC)'s CTSO Position: Q2 2026 in Review
Tower Research Capital (TRC) opened a new position in Cytosorbents Corp (CTSO) in Q2 2026: 511 shares worth $3.82K. The stake represents ﹤0.01% of the portfolio and ranks #4467 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CTSO as recently as Q4 2025.
Tower Research Capital (TRC) first reported a position in CTSO in Q1 2015 and has held it in 38 quarters since. The position peaked at $297K in Q3 2020. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Tower Research Capital (TRC) held 511 shares of Cytosorbents Corp worth $3.82K as of Q2 2026.
- Cytosorbents Corp was a new Tower Research Capital (TRC) position in Q2 2026.
- Cytosorbents Corp made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4467 holding.
- Tower Research Capital (TRC) first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 38 quarters since.
- Tower Research Capital (TRC)'s Cytosorbents Corp position peaked at $297K in Q3 2020.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.